The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...
GlobalData on MSN
FDA accepts Beren Therapeutics’ NDA for Niemann-Pick disease
The submission includes data indicating a meaningful survival benefit for infantile-onset NPC patients treated with adrabetadex.
Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.
WE BEGIN WITH BREAKING NEWS. THAT BREAKING NEWS TONIGHT. GOVERNOR GAVIN NEWSOM JUST SIGNED A BILL BANNING LAWMAKERS FROM USING SECRETIVE NONDISCLOSURE AGREEMENTS. THANK YOU FOR JOINING US HERE AT TEN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results